N-(ARYLALKYL)-1H-INDOLE-2-SULFONIC ACID AMIDE COMPOUNDS AND THEIR THERAPEUTIC USE AS CANNABINOID ALLOSTERIC MODULATORS

Iain Robert Greig (Inventor), Ruth Alexandra Ross (Inventor), Laurent Alain Claude Trembleau (Inventor), Roger Guy Pertwee (Inventor), Mostafa H Abdelrahman (Inventor)

Research output: Patent

Abstract

The present invention pertains generally to the field of therapeutic compounds.
5 More specifically the present invention pertains to certain N-(arylalkyl)-1H-indole-
2-sulfonic acid amide compounds that, inter alia, inhibit cannabinoid receptor signalling.
The present invention also pertains to pharmaceutical compositions comprising such
compounds, and the use of such compounds and compositions, both in vitro and in vivo,
to inhibit cannabinoid receptor signalling; to treat disorders that are ameliorated by the
10 inhibition of cannabinoid receptor signalling; to treat metabolic syndrome, type-2 diabetes,
dyslipidaemia, obesity, eating disorders, cardiovascular diseases and disorders, and
other conditions as described herein
Original languageEnglish
Patent numberWO2012117216
IPCWO2012117216
Publication statusPublished - 28 Feb 2011

Fingerprint Dive into the research topics of 'N-(ARYLALKYL)-1H-INDOLE-2-SULFONIC ACID AMIDE COMPOUNDS AND THEIR THERAPEUTIC USE AS CANNABINOID ALLOSTERIC MODULATORS'. Together they form a unique fingerprint.

  • Cite this